Reviewer's report
Title:The Potential Therapeutic Effect of Melatonin in Gastro-esophageal Reflux
Disease
Version: 5Date:12 October 2009
Reviewer: Stanis&#322;aw Konturek
Reviewer's report:
Major Compulsory Revisions:
I read this revised paper, but, unfortunately, found that none of my major
compusatory revisions has been seriously considered and no additional
requested results have been included into the revised paper. (1) I requested that
gastric acid secretion should be measured in patients treated with melatonin
alone and with melatonin combined with gastric inhibitors. The answer was that
measurement of esophageal pH should be sufficiently refelect the decrease in
gastric HCl secretion by these drugs. (2) Since gastrin is potent contrictive agent
of the LES, the plasma levels of gastric should be measured, particularly that the
blood samples were taken for measurement of plasma levels of melatonin. No
data with plasma gastrin have been included. (3)I asked to include the data with
esophageal mucosal histology to see whether melatonin has direct ameliorating
effect on the inflammatory changes of esophageal mucosa. This request was
considered for future study (!).
Minor Essential Revisions:
Melatonin as potent antioxidant is known, at least from experimental studies in
animals, to affect the COX-PG and NOS-NO systems in the esophageal mucosa,
but again this was considered as future project of the study. Based on the facts
that actually none of my requests has been answered by including appropriate
data I would not recommend this the paper in the present for the publication in
BMC Gastroenterology Journal.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I do not have any non-financial competing interests in relation to this paper.
Reviewer's report
Title:The Potential Therapeutic Effect of Melatonin in Gastro-esophageal Reflux
Disease
Version: 5Date:12 October 2009
Reviewer: Stanis&#322;aw Konturek
Reviewer's report:
Major Compulsory Revisions:
I read this revised paper, but, unfortunately, found that none of my major
compusatory revisions has been seriously considered and no additional
requested results have been included into the revised paper. (1) I requested that
gastric acid secretion should be measured in patients treated with melatonin
alone and with melatonin combined with gastric inhibitors. The answer was that
measurement of esophageal pH should be sufficiently refelect the decrease in
gastric HCl secretion by these drugs. (2) Since gastrin is potent contrictive agent
of the LES, the plasma levels of gastric should be measured, particularly that the
blood samples were taken for measurement of plasma levels of melatonin. No
data with plasma gastrin have been included. (3)I asked to include the data with
esophageal mucosal histology to see whether melatonin has direct ameliorating
effect on the inflammatory changes of esophageal mucosa. This request was
considered for future study (!).
Minor Essential Revisions:
Melatonin as potent antioxidant is known, at least from experimental studies in
animals, to affect the COX-PG and NOS-NO systems in the esophageal mucosa,
but again this was considered as future project of the study. Based on the facts
that actually none of my requests has been answered by including appropriate
data I would not recommend this the paper in the present for the publication in
BMC Gastroenterology Journal.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I do not have any non-financial competing interests in relation to this paper.
Please review this paper.
user
Reviewer's report
Title:The Potential Therapeutic Effect of Melatonin in Gastro-esophageal Reflux
Disease
Version: 5Date:12 October 2009
Reviewer: Stanis&#322;aw Konturek
Reviewer's report:
Major Compulsory Revisions:
I read this revised paper, but, unfortunately, found that none of my major
compusatory revisions has been seriously considered and no additional
requested results have been included into the revised paper. (1) I requested that
gastric acid secretion should be measured in patients treated with melatonin
alone and with melatonin combined with gastric inhibitors. The answer was that
measurement of esophageal pH should be sufficiently refelect the decrease in
gastric HCl secretion by these drugs. (2) Since gastrin is potent contrictive agent
of the LES, the plasma levels of gastric should be measured, particularly that the
blood samples were taken for measurement of plasma levels of melatonin. No
data with plasma gastrin have been included. (3)I asked to include the data with
esophageal mucosal histology to see whether melatonin has direct ameliorating
effect on the inflammatory changes of esophageal mucosa. This request was
considered for future study (!).
Minor Essential Revisions:
Melatonin as potent antioxidant is known, at least from experimental studies in
animals, to affect the COX-PG and NOS-NO systems in the esophageal mucosa,
but again this was considered as future project of the study. Based on the facts
that actually none of my requests has been answered by including appropriate
data I would not recommend this the paper in the present for the publication in
BMC Gastroenterology Journal.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I do not have any non-financial competing interests in relation to this paper.
assistant